TY - JOUR
T1 - Oral curcumin in elective abdominal aortic aneurysm repair
T2 - A multicentre randomized controlled trial
AU - Garg, Amit X.
AU - Devereaux, P. J.
AU - Hill, Andrew
AU - Sood, Manish
AU - Aggarwal, Bharat
AU - Dubois, Luc
AU - Hiremath, Swapnil
AU - Guzman, Randolph
AU - Iyer, Vikram
AU - James, Matthew
AU - McArthur, Eric
AU - Moist, Louise
AU - Ouellet, George
AU - Parikh, Chirag R.
AU - Schumann, Virginia
AU - Sharan, Sumit
AU - Thiessen-Philbrook, Heather
AU - Tobe, Sheldon
AU - Wald, Ron
AU - Walsh, Michael
AU - Weir, Matthew
AU - Pannu, Neesh
N1 - Publisher Copyright:
© 2018 Joule Inc. or its licensors.
PY - 2018/10/29
Y1 - 2018/10/29
N2 - BACKGROUND: Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a singlecentre randomized human trial. We sought to test whether perioperative oral curcumin (compared with plac ebo) affects the inflammatory response and risk of postrepair complications after elective abdominal aortic aneurysm repair in humans. METHODS: We conducted a parallelgroup, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 biomarkers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N-terminal pro-B-type natriuretic peptide and plasma highsensitivity C-reactive protein). RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers (p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9). INTERPRETATION: Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media.
AB - BACKGROUND: Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a singlecentre randomized human trial. We sought to test whether perioperative oral curcumin (compared with plac ebo) affects the inflammatory response and risk of postrepair complications after elective abdominal aortic aneurysm repair in humans. METHODS: We conducted a parallelgroup, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 biomarkers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N-terminal pro-B-type natriuretic peptide and plasma highsensitivity C-reactive protein). RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers (p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9). INTERPRETATION: Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media.
UR - http://www.scopus.com/inward/record.url?scp=85055612695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055612695&partnerID=8YFLogxK
U2 - 10.1503/cmaj.180510
DO - 10.1503/cmaj.180510
M3 - Article
C2 - 30373740
AN - SCOPUS:85055612695
SN - 0820-3946
VL - 190
SP - E1273-E1280
JO - CMAJ
JF - CMAJ
IS - 43
ER -